19 June 2018 | News
This project will generate one of the largest data-banks of preterm birth samples, enabling statistically robust confirmation of Carmentix's prognostic tool
Carmentix Pte. Ltd. is proud to announce a research collaboration with The University of Melbourne (UoM), The Chinese University Hong Kong (CUHK) and The Henan Province People's Hospital for a clinical Preterm Birth study to validate Carmentix's prognostic tool for predicting premature birth.
This multi-centre collaboration follows on from the retrospective study completed in August 2017 with the University of Melbourne, which validated Carmentix's novel proprietary biomarkers in combination with UoM's previously discovered biomarkers."Carmentix, with the backing of Esco Ventures, has achieved an ambitious milestone in identifying novel biomarkers. We are excited to support Carmentix to pursue a broader validation of the technology to establish its ability to predict preterm birth, weeks or months before symptoms," said XiangQian (XQ) Lin, Executive Chairman of Carmentix.
In this multi-faceted collaboration, dedicated clinicians, midwives and scientists will collect over 15,000 samples over the next 2-3 years. This project will generate one of the largest data-banks of preterm birth samples, enabling statistically robust confirmation of Carmentix's prognostic tool.